Toxic epidermal necrolysis and neutropaenia: Complications of omeprazole

Thakor, Avnesh S.; Burke, Ailbhe; Handfield‐Jones, S.; Sinha, Ayush; Palmér, Mats; Burns, Alys

doi:10.1111/j.1440-0960.2009.00540.x

Cited by 15 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first report of a delayed HSR, published in 1992, was a toxic epidermal necrolysis in a 72-year-old woman after 2 weeks of therapy with omeprazole [8]. Afterward, other case reports of epidermal necrolysis and severe exfoliative dermatitis caused by omeprazole, lansoprazole, and esomeprazole have been published [10,48,[56][57][58].…”

Section: Delayed Hypersensitivity Reactionsmentioning

confidence: 99%

Hypersensitivity Reactions to Proton Pump Inhibitors

Lombardo

Bonadonna

2015

Curr Treat Options Allergy

View full text Add to dashboard Cite

Proton pump inhibitors I Drug allergy I Anaphylaxis I Adverse drug reaction I Drug hypersensitivity Opinion Statement Proton pump inhibitors (PPIs) are drugs widely used and usually well tolerated. However, cases of immediate or cell-mediated hypersensitivity reactions due to all PPIs, with the exception of the newest dexlansoprazole and tenatoprazole, have been described. In the case of suspected IgE-mediated reaction skin test (prick test and intradermal test) with nonirritant drug concentration published is safe and highly specific (100 %) with a PPV of 100 %. Thus, oral provocation test should be performed only in case of negative results to rule out definitely the diagnosis. In the case of possible cell-mediated hypersensitivity reaction, a delayed reading of intradermal test, at least after 24 and 48 h, and patch test should be performed, but we do not have standardized procedures so far. Cross-reactivity among all PPIs is not a dogma, in fact, three patterns of cross-reactivity have been described. Thus, in patients with ascertained allergy to a PPI, a complete evaluation (skin test and oral provocation test) of all five PPIs available helps to identify a safe alternative.

show abstract

Section: Delayed Hypersensitivity Reactionsmentioning

confidence: 99%

Hypersensitivity Reactions to Proton Pump Inhibitors

Lombardo

Bonadonna

2015

Curr Treat Options Allergy

View full text Add to dashboard Cite

show abstract

“…Life threatening dermatoses secondary to proton pump inhibitors have also been described, albeit rarely [ 30 , 37 , 38 ]. To the best of my knowledge, proton pump inhibitor-induced Sweet’s syndrome has not previously been observed.…”

Section: Discussionmentioning

confidence: 99%

Proton pump inhibitor-induced Sweet’s syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer

Cohen

2015

Dermatol Pract Concept

View full text Add to dashboard Cite

Background: Sweet’s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug. Proton pump inhibitors selectively inhibit gastric parietal cell H+-K+-adenosine triphosphatase and are most commonly used for the treatment of gastroesophageal reflux disease. Purpose: Proton pump inhibitor-associated Sweet’s syndrome is described in a woman with recurrent breast cancer. Methods: PubMed was used to search the following terms, separately and in combination: acute febrile neutrophilic dermatosis, breast cancer, malignancy, paraneoplastic, proton pump inhibitor, and Sweet’s syndrome. All papers were reviewed and relevant manuscripts, along with their reference citations, were evaluated. Results: Proton pump inhibitors have previously been associated with cutaneous adverse reactions including maculopapular rash, subacute cutaneous lupus erythematosus and toxic epidermal necrolysis. However, drug-induced Sweet’s syndrome has not been observed in patients receiving proton pump inhibitors. The reported woman developed Sweet’s syndrome after initial exposure and subsequent repeat challenge to proton pump inhibitors; subsequent studies also observed recurrence of her breast cancer presenting as metastases to her stomach and bone. Conclusions: Drug-induced Sweet’s syndrome has most commonly been associated with granulocyte colony stimulating factor in oncology patients. Malignancy-associated Sweet’s syndrome has been observed in patients with solid tumors, including breast cancer. Confirmation of proton pump inhibitor-induced Sweet’s syndrome, by repeat challenge with another medication in the same class of drug, was observed in a woman with breast cancer; although the subsequent discovery of recurrent breast cancer presenting as gastric mucosa and vertebral metastases also raises the possibility of concurrent paraneoplastic Sweet’s syndrome, her Sweet’s syndrome symptoms and lesions resolved without recurrence while her recurrent metastatic visceral malignancy persisted. In summary, medication-associated Sweet’s syndrome can occur in oncology patients and proton pump inhibitors should be added to the list of medications associated with the potential to cause drug-induced Sweet’s syndrome.

show abstract

“…1,3,7 Other hematological features that have been reported include anemia, throm-bocytopenia, lymphopenia and disseminated intravascular coagulation. 2,9,11,[14][15][16] However, these features were not consistently seen in the different case series, and their presence and prevalence differs between the case series.…”

Section: Introductionmentioning

confidence: 92%